(Total Views: 824)
Posted On: 02/10/2021 3:37:50 AM
Post# of 148984
When I read the FDA announcement about 7:30pm ET....I almost had a "personal accident" because I thought it was about LL. Then I noted that it was for Lilly's bamlanivimab and etesevimab administered together when I read the article:
https://www.fda.gov/news-events/press-announc...covid-19-0
Interesting that a dual-drug treatment gets two different codes - one for each. Didn't see that coming in one announcement. Then I looked over my notes and realized almost all the pieces of the ICD-10-PCS 2021 codes for COVID were nearly there.
The AZ/J&J is almost a 100% shoe-in.
https://www.fda.gov/news-events/press-announc...otech-incs
The "Unknown mAB" is most likely "lenzi" which is gearing up for manufacturing right now. The tech transfer with their new CDMO is just starting....it took CytoDyn and Samsung Biologics a year to get it done....they are looking to be delivering by the end of the year. Still has to go through the manufacturing approval process.
https://www.contractpharma.com/contents/view_...agreement/
https://www.fda.gov/news-events/press-announc...covid-19-0
Interesting that a dual-drug treatment gets two different codes - one for each. Didn't see that coming in one announcement. Then I looked over my notes and realized almost all the pieces of the ICD-10-PCS 2021 codes for COVID were nearly there.
The AZ/J&J is almost a 100% shoe-in.
https://www.fda.gov/news-events/press-announc...otech-incs
The "Unknown mAB" is most likely "lenzi" which is gearing up for manufacturing right now. The tech transfer with their new CDMO is just starting....it took CytoDyn and Samsung Biologics a year to get it done....they are looking to be delivering by the end of the year. Still has to go through the manufacturing approval process.
https://www.contractpharma.com/contents/view_...agreement/
(1)
(0)Scroll down for more posts ▼
